|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 8701 |
FusionGeneSummary for CSTB_EXT2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CSTB_EXT2 | Fusion gene ID: 8701 | Hgene | Tgene | Gene symbol | CSTB | EXT2 | Gene ID | 1476 | 2132 |
| Gene name | cystatin B | exostosin glycosyltransferase 2 | |
| Synonyms | CPI-B|CST6|EPM1|EPM1A|PME|STFB|ULD | SOTV|SSMS | |
| Cytomap | 21q22.3 | 11p11.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | cystatin-Bcystatin B (stefin B)liver thiol proteinase inhibitor | exostosin-2N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferaseglucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferasemultiple exostoses protein 2multiple exostosis 2putativ | |
| Modification date | 20180523 | 20180522 | |
| UniProtAcc | P04080 | Q93063 | |
| Ensembl transtripts involved in fusion gene | ENST00000291568, | ENST00000533608, ENST00000358681, ENST00000395673, ENST00000343631, ENST00000529186, | |
| Fusion gene scores | * DoF score | 4 X 4 X 2=32 | 5 X 5 X 3=75 |
| # samples | 4 | 5 | |
| ** MAII score | log2(4/32*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(5/75*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: CSTB [Title/Abstract] AND EXT2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CSTB | GO:0010466 | negative regulation of peptidase activity | 6203523 |
| Hgene | CSTB | GO:0045861 | negative regulation of proteolysis | 3488317 |
| Tgene | EXT2 | GO:0006024 | glycosaminoglycan biosynthetic process | 12907669 |
| Tgene | EXT2 | GO:0033692 | cellular polysaccharide biosynthetic process | 12907669 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | AA554222 | CSTB | chr21 | 45193977 | + | EXT2 | chr11 | 44200638 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-intron | ENST00000291568 | ENST00000533608 | CSTB | chr21 | 45193977 | + | EXT2 | chr11 | 44200638 | - |
| intron-intron | ENST00000291568 | ENST00000358681 | CSTB | chr21 | 45193977 | + | EXT2 | chr11 | 44200638 | - |
| intron-intron | ENST00000291568 | ENST00000395673 | CSTB | chr21 | 45193977 | + | EXT2 | chr11 | 44200638 | - |
| intron-intron | ENST00000291568 | ENST00000343631 | CSTB | chr21 | 45193977 | + | EXT2 | chr11 | 44200638 | - |
| intron-intron | ENST00000291568 | ENST00000529186 | CSTB | chr21 | 45193977 | + | EXT2 | chr11 | 44200638 | - |
Top |
FusionProtFeatures for CSTB_EXT2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CSTB | EXT2 |
| This is an intracellular thiol proteinase inhibitor.Tightly binding reversible inhibitor of cathepsins L, H and B. | Glycosyltransferase required for the biosynthesis ofheparan-sulfate. The EXT1/EXT2 complex possesses substantiallyhigher glycosyltransferase activity than EXT1 or EXT2 alone.Appears to be a tumor suppressor. Required for the exosomalrelease of SDCBP, CD63 and syndecan (PubMed:22660413).{ECO:0000269|PubMed:22660413}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for CSTB_EXT2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for CSTB_EXT2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for CSTB_EXT2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for CSTB_EXT2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | CSTB | C0751785 | Unverricht-Lundborg Syndrome | 3 | CTD_human;ORPHANET;UNIPROT |
| Hgene | CSTB | C0027626 | Neoplasm Invasiveness | 2 | CTD_human |
| Hgene | CSTB | C0017636 | Glioblastoma | 1 | CTD_human |
| Hgene | CSTB | C0025286 | Meningioma | 1 | CTD_human |
| Hgene | CSTB | C0279626 | Squamous cell carcinoma of esophagus | 1 | CTD_human |
| Tgene | EXT2 | C1851413 | EXOSTOSES, MULTIPLE, TYPE II | 9 | CTD_human;UNIPROT |
| Tgene | EXT2 | C0015306 | Hereditary Multiple Exostoses | 1 | CTD_human;HPO;ORPHANET |
| Tgene | EXT2 | C4225248 | SEIZURES, SCOLIOSIS, AND MACROCEPHALY SYNDROME | 1 | ORPHANET;UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|